Survey of technology facilitating kinase inhibitor development

All from the perspective of service companies not doing proprietary R & D.

Memorable quote:

"The focus on single purified kinase inhibitor screening has lead to poor efficacy in development, because of the ability of tumor cells to compensate and circumvent a block of a single node in the signaling network. Hence, there is a need for a systems biology approach to assay the activity of the signaling pathways downstream of the kinase targets," says Steve Horrigan, Ph.D., interim vp of research at Avalon Pharmaceuticals (www.avalonrx.com).

When added to the problem of genetic mutations, over the long term, can anyone beat the cancer's survival instincts?